文献速递流行病学与生物统计基础与转化研究

疟疾感染与G6PD活性的关联:孟加拉国临床试验、横断面与病例对照分析

Glucose-6-phosphate dehydrogenase activity in individuals with and without malaria: Analysis of clinical trial, cross-sectional and case-control data from Bangladesh.
PubMed 文献 · PLoS Med · 2021-04-23

该研究基于孟加拉国三项互补研究,比较疟疾患者与无疟疾者的G6PD活性。急性疟疾患者G6PD活性显著高于无疟疾者,且G6PD缺乏者在感染时酶活性可能高于预期,提示伯氨喹诱发的溶血风险可能减弱。

要点

  • 急性疟疾患者G6PD活性中位数7.9 U/g Hb,高于无疟疾者的6.9 U/g Hb。
  • 疟疾患者中G6PD活性<70%的比例为7.7%,低于无或亚显微疟疾者的25.0%。
  • 有疟疾史与无疟疾史者的G6PD活性及缺乏比例无显著差异。

核心结论

  • 急性疟疾患者G6PD活性显著高于无疟疾者,且不能归因于G6PD缺乏的保护效应。
  • G6PD缺乏的疟疾患者酶活性可能高于预期,伯氨喹诱导溶血风险可能较未感染时减弱。

研究设计与样本

  • 前瞻性单臂临床试验纳入175例无并发症疟疾患者,2014–2015年。
  • 横断面调查纳入999人,2015–2016年。
  • 匹配病例对照研究纳入506例无寄生虫血症者,2020年。

主要发现

  • 横断面与临床试验中,15.5%(182/1,174)参与者经显微镜或RDT检出外周寄生虫血症,3.1%(36/1,174)仅PCR阳性,81.4%(956/1,174)无寄生虫血症。
  • 无寄生虫血症者G6PD活性中位数6.9 U/g Hb(IQR 5.2–8.6),低于显微镜或RDT检出者的7.9 U/g Hb(IQR 6.6–9.8,p<0.001)。
  • 仅PCR阳性者G6PD活性中位数6.1 U/g Hb(IQR 4.8–8.6),与无寄生虫血症者相似(p=0.312)。
  • 疟疾患者中G6PD活性<70%的比例为7.7%(14/182),低于无或亚显微疟疾者的25.0%(248/992),OR 0.25(95%CI 0.14–0.44,p<0.001)。
  • 病例对照研究中,有疟疾史者G6PD活性中位数10.3 U/g Hb(IQR 8.8–12.2),无史者为10.2 U/g Hb(IQR 8.7–11.8,p=0.323);G6PD活性<70%比例分别为11.5%(29/253)和15.4%(39/253),OR 0.7(95%CI 0.41–1.23,p=0.192)。

临床怎么用

  • 疟疾感染时G6PD活性可能升高,解读G6PD缺乏状态需考虑感染状态。
  • G6PD缺乏的疟疾患者使用伯氨喹时溶血风险可能低于未感染时,但仍需谨慎评估。

局限性

  • 临床试验与横断面调查非同期进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glucose-6-phosphate dehydrogenase (G6PD) activity is dependent upon G6PD genotype and age of the red blood cell (RBC) population, with younger RBCs having higher activity. Peripheral parasitemia with Plasmodium spp. induces hemolysis, replacing older RBCs with younger cells with higher G6PD activity. This study aimed to assess whether G6PD activity varies between individuals with and without malaria or a history of malaria. METHODS AND FINDINGS: Individuals living in the Chittagong Hill Tracts of Bangladesh were enrolled into 3 complementary studies: (i) a prospective, single-arm clinical efficacy trial of patients (n = 175) with uncomplicated malaria done between 2014 and 2015, (ii) a cross-sectional survey done between 2015 and 2016 (n = 999), and (iii) a matched case-control study of aparasitemic individuals with and without a history of malaria done in 2020 (n = 506). G6PD activity was compared between individuals with and without malaria diagnosed by microscopy, rapid diagnostic test (RDT), or polymerase chain reaction (PCR), and in aparasitemic participants with and without a history of malaria. In the cross-sectional survey and clinical trial, 15.5% (182/1,174) of participants had peripheral parasitemia detected by microscopy or RDT, 3.1% (36/1,174) were positive by PCR only, and 81.4% (956/1,174) were aparasitemic. Aparasitemic individuals had significantly lower G6PD activity (median 6.9 U/g Hb, IQR 5.2-8.6) than those with peripheral parasitemia detected by microscopy or RDT (7.9 U/g Hb, IQR 6.6-9.8, p < 0.001), but G6PD activity similar to those with parasitemia detected by PCR alone (submicroscopic parasitemia) (6.1 U/g Hb, IQR 4.8-8.6, p = 0.312). In total, 7.7% (14/182) of patients with malaria had G6PD activity < 70% compared to 25.0% (248/992) of participants with submicroscopic or no parasitemia (odds ratio [OR] 0.25, 95% CI 0.14-0.44, p < 0.001). In the case-control study, the median G6PD activity was 10.3 U/g Hb (IQR 8.8-12.2) in 253 patients with a history of malaria and 10.2 U/g Hb (IQR 8.7-11.8) in 253 individuals without a history of malaria (p = 0.323). The proportion of individuals with G6PD activity < 70% was 11.5% (29/253) in the cases and 15.4% (39/253) in the controls (OR 0.7, 95% CI 0.41-1.23, p = 0.192). Limitations of the study included the non-contemporaneous nature of the clinical trial and cross-sectional survey. CONCLUSIONS: Patients with acute malaria had significantly higher G6PD activity than individuals without malaria, and this could not be accounted for by a protective effect of G6PD deficiency. G6PD-deficient patients with malaria may have higher than expected G6PD enzyme activity and an attenuated risk of primaquine-induced hemolysis compared to the risk when not infected.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Ley B, Alam MS, Kibria MG, et al. Glucose-6-phosphate dehydrogenase activity in individuals with and without malaria: Analysis of clinical trial, cross-sectional and case-control data from Bangladesh. PLoS Med. 2021. PMID: 33891581. doi:10.1371/journal.pmed.1003576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。